Free Trial
NASDAQ:EOLS

Evolus (EOLS) Stock Price, News & Analysis

$15.27
+0.09 (+0.59%)
(As of 09:07 AM ET)
Today's Range
$15.27
$15.27
50-Day Range
$10.93
$15.89
52-Week Range
$7.44
$16.29
Volume
185 shs
Average Volume
568,328 shs
Market Capitalization
$955.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67

Evolus MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.9% Upside
$21.67 Price Target
Short Interest
Bearish
7.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.61mentions of Evolus in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$138,326 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.64) to ($0.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.90 out of 5 stars

Medical Sector

192nd out of 911 stocks

Pharmaceutical Preparations Industry

78th out of 423 stocks

EOLS stock logo

About Evolus Stock (NASDAQ:EOLS)

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Stock Price History

EOLS Stock News Headlines

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 3,276 Shares
Evolus, Inc. (NASDAQ:EOLS) CMO Sells $89,251.35 in Stock
Ready for Lockdown 2.0?
Remember the Covid-19 lockdown? Countless businesses forcefully shut … But get this: Another kind of lockdown is close at hand. And it could be far more devastating than the lockdown of Covid-19.
Evolus' (EOLS) Overweight Rating Reaffirmed at Cantor Fitzgerald
Evolus, Inc. (EVL.F)
EOLS Aug 2024 15.000 put (EOLS240816P00015000)
Ready for Lockdown 2.0?
Remember the Covid-19 lockdown? Countless businesses forcefully shut … But get this: Another kind of lockdown is close at hand. And it could be far more devastating than the lockdown of Covid-19.
Evolus Continues To Make Progress
Here's what Wall Street expects from Evolus's earnings
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/31/2024
Today
9/12/2024
Next Earnings (Estimated)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.67
High Stock Price Target
$27.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+41.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-61,690,000.00
Pretax Margin
-22.33%

Debt

Sales & Book Value

Annual Sales
$237.26 million
Book Value
($0.36) per share

Miscellaneous

Free Float
58,781,000
Market Cap
$955.90 million
Optionable
Optionable
Beta
1.31
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David MoatazediMr. David Moatazedi (Age 46)
    President, CEO & Director
    Comp: $1.75M
  • Ms. Sandra Beaver (Age 46)
    Chief Financial Officer
    Comp: $740.15k
  • Dr. Rui Avelar C.CFP (Age 62)
    Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development
    Comp: $823.19k
  • Mr. Nareg Sagherian
    Head of Global Investor Relations & Corporate Communications
  • Mr. Jeffrey J. Plumer
    General Counsel
  • Mr. Kurt Knab
    Vice President of Sales
  • Ms. Tomoko Yamagishi-Dressler
    Chief Marketing Officer
  • Ms. Jessica Novak
    Senior Vice President of Human Resources

EOLS Stock Analysis - Frequently Asked Questions

How have EOLS shares performed this year?

Evolus' stock was trading at $10.53 at the beginning of the year. Since then, EOLS shares have increased by 45.0% and is now trading at $15.27.
View the best growth stocks for 2024 here
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company earned $66.91 million during the quarter, compared to analysts' expectations of $65.06 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Evolus IPO?

Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Evolus' top institutional shareholders include Great Point Partners LLC (3.92%), Stonepine Capital Management LLC (2.65%), Assenagon Asset Management S.A. (1.51%) and Millennium Management LLC (1.44%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, Tomoko Yamagishi-Dressler, David N Gill, Robert Hayman and Crystal Muilenburg.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Sorrento Therapeutics (SRNE).

This page (NASDAQ:EOLS) was last updated on 9/12/2024 by MarketBeat.com Staff

From Our Partners